Home > Haematology > EHA 2020 > Daratumumab for light-chain amyloidosis

Daratumumab for light-chain amyloidosis

The ANDROMEDA study demonstrated clear clinical benefit when adding subcutaneous (SC) daratumumab to a combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) for patients with newly diagnosed light-chain (AL) amyloidosis.

Chemotherapy-based combinations are commonly used in AL amyloidosis, but more effective treatments are needed. Dr Efstathios Kastritis (National and Kapodistrian University of Athens, Greece) presented the phase 3 ANDROMEDA study, which evaluated subcutaneous (SC) daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) compared with CyBorD alone in newly diagnosed patients with AL amyloidosis [1].

In total, 388 patients with newly diagnosed with AL amyloidosis were randomised to receive treatment with either CyBorD alone (n=193) or with the addition of SC daratumumab (n=195; 1,800 mg Q4W). The primary endpoint of the s...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on